NCT05145569 is a Phase 2 clinical trial of Carboplatin AUC 5 and paclitaxel in Ovarian Cancer, sponsored by Haider Mahdi.

Who is sponsoring NCT05145569?

NCT05145569 is sponsored by Haider Mahdi.

What drugs are being tested in NCT05145569?

Interventions in NCT05145569: Carboplatin AUC 5 and paclitaxel, HCW9218.

What condition does NCT05145569 study?

NCT05145569 studies Ovarian Cancer.

Is NCT05145569 still recruiting?

NCT05145569 is currently withdrawn. Last updated 1 January 2025.

Last reviewed 2025-01-01 · How we verify

NCT05145569

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer

Withdrawn Phase 2 Last updated 1 January 2025

What this trial tests

Phase 2 trial testing Carboplatin AUC 5 and paclitaxel in Ovarian Cancer. Withdrawn.

Timeline

10 May 2024

Primary endpoint
31 May 2026

31 January 2028

Quick facts

Lead sponsor	Haider Mahdi
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	10 May 2024
Primary completion	31 May 2026
Estimated completion	31 January 2028

Drugs / interventions tested

Carboplatin AUC 5 and paclitaxel — full drug profile →
HCW9218 — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Haider Mahdi — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the safety, tolerability, and anti-tumor activity of HCW9218 in combination with chemotherapy will be assessed in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies.
Shi ZD, Pang K, Wu ZX, Dong Y, et al · · 2023 · cited 168× · PMID 36906600 · DOI 10.1038/s41392-023-01383-x
TGF-beta signal transduction: biology, function and therapy for diseases.
Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
The difficulty in translating the preclinical success of combined TGFβ and immune checkpoint inhibition to clinical trial.
Metropulos AE, Munshi HG, Principe DR. · · 2022 · cited 59× · PMID 36455409 · DOI 10.1016/j.ebiom.2022.104380
Macrophage and monocyte subsets as new therapeutic targets in cancer immunotherapy.
Fendl B, Berghoff AS, Preusser M, Maier B. · · 2023 · cited 34× · PMID 36731326 · DOI 10.1016/j.esmoop.2022.100776
Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513
Unraveling the Role of the Tumor Extracellular Matrix to Inform Nanoparticle Design for Nanomedicine.
Cassani M, Fernandes S, Pagliari S, Cavalieri F, et al · · 2025 · cited 24× · PMID 39629891 · DOI 10.1002/advs.202409898
Tumor microenvironment as niche constructed by cancer stem cells: Breaking the ecosystem to combat cancer.
Zhong H, Zhou S, Yin S, Qiu Y, et al · · 2025 · cited 16× · PMID 38866179 · DOI 10.1016/j.jare.2024.06.014

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Haider Mahdi trials

Trials by the same sponsor.

NCT06161493 — ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05145569 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Haider Mahdi
Last refreshed: 1 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing